Proteogenomic Translational Research for Clinical Proteomic Tumor Analysis Consortium (U01) | RFA CA 15 022

Opportunity Information: Apply for RFA CA 15 022

The Proteogenomic Translational Research for Clinical Proteomic Tumor Analysis Consortium (U01) funding opportunity (RFA-CA-15-022) is a National Cancer Institute (NCI), National Institutes of Health (NIH) cooperative agreement designed to support the next phase of the Clinical Proteomic Tumor Analysis Consortium (CPTAC). The central idea is to capitalize on rapid improvements in cancer proteomics and cancer genomics to better understand how tumors work at multiple biological levels, and to make the resulting datasets, methods, and other research resources broadly available to the wider scientific community. Unlike a standard research grant, the U01 cooperative agreement structure signals that awardees should expect substantial scientific involvement from NIH/NCI staff, including coordination and collaboration across the consortium.

Scientifically, the program emphasizes integrated proteomic and proteogenomic research across several cancer types. In practical terms, this means studying not only DNA and RNA alterations in tumors, but also measuring proteins and protein modifications at scale, then connecting those protein-level patterns back to genomic abnormalities. The goal is to map the complexity of tumor proteomes, identify how genomic changes actually manifest in protein networks and pathways, and highlight mechanisms that may not be obvious from sequencing alone. By supporting multi-cancer efforts, the FOA aims to reveal both shared and cancer-type-specific biology, helping the field move from catalogs of mutations to clearer, actionable models of tumor behavior.

A second, explicitly highlighted thrust is translational research aimed at clinically relevant questions. The FOA calls attention to the potential for proteomic and proteogenomic approaches to improve real-world decision-making, such as predicting which therapies are most likely to work for a particular patient’s tumor. This points to work that bridges discovery science and clinical application: developing or refining predictive signatures, identifying therapy-responsive pathways, clarifying resistance mechanisms, and improving the interpretation of tumor molecular profiles in a way that could ultimately inform treatment selection. The consortium framing also implies an expectation that outputs will be standardized, reproducible, and shared in formats that other researchers can reuse and build upon.

From an administrative and funding perspective, this is a discretionary federal opportunity using the cooperative agreement funding instrument (U01) within the health and education-related activity categories. The listed CFDA numbers are 93.393, 93.394, and 93.396. The opportunity anticipated about three awards, with an award ceiling of $910,000. The original closing date shown is May 11, 2016, and the opportunity record was created on November 2, 2015, reflecting that this was a specific cycle or reissuance tied to that time period.

Eligibility is broad across U.S.-based organizations and governmental entities, including state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations other than federally recognized tribal governments; public housing authorities/Indian housing authorities; nonprofits (both 501(c)(3) and non-501(c)(3), excluding institutions of higher education in those categories); for-profit organizations other than small businesses; and small businesses. The FOA also explicitly notes additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, regional organizations, Indian/Native American tribal governments other than federally recognized, and U.S. territories or possessions.

Restrictions related to foreign participation are spelled out clearly. Non-domestic (non-U.S.) entities and non-domestic (non-U.S.) institutions are not eligible to apply, and non-domestic components of U.S. organizations are also not eligible to apply. However, foreign components are allowed as defined in the NIH Grants Policy Statement, meaning a U.S. applicant organization may include certain types of foreign involvement consistent with NIH policy, even though the applicant institution itself must be domestic and foreign institutional applicants are excluded.

Overall, the opportunity is best understood as a coordinated, consortium-based investment in large-scale, high-value proteogenomic cancer research that produces shared community resources while also pushing toward clinically meaningful translation. It supports teams that can generate robust proteomic and proteogenomic data, connect those data to genomic alterations, and work collaboratively under NIH/NCI involvement to accelerate discovery and improve the future clinical utility of tumor molecular profiling.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Proteogenomic Translational Research for Clinical Proteomic Tumor Analysis Consortium (U01)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.394, 93.396.
• This funding opportunity was created on 2015-11-02.
• Applicants must submit their applications by 2016-05-11. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $910,000.00 in funding.
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA CA 15 022

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: